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Abstract
The hallmark of Parkinson’s disease (PD OMIM #168600) is the degeneration of the nigral dopaminergic system
affecting approximately 1% of the human population older than 65. In pursuit of genetic factors contributing to
PD, linkage and association studies identiﬁed several susceptibility genes. The majority of these genes are expressed
by the dopamine-producing neurons in the substantia nigra. We, therefore, propose expression by these neurons as
a selection criterion, to narrow down, in a rational manner, the number of candidate genes in orphan PD loci,
where no mutation has been associated thus far. We determined the corresponding human chromosome locations of
1435 murine cDNA fragments obtained from murine expression analyses of nigral dopaminergic neurons and combined
these data with human linkage studies. These fragments represent 19 genes within orphan OMIM PD loci. We used the
same approach for independent association studies and determined the genes in neighborhood to the peaks with the
highest LOD score value. Our approach did not make any assumptions about disease mechanisms, but it, nevertheless,
revealed a-synuclein, NR4A2 (Nurr1), and the tau genes, which had previously been associated to PD. Furthermore,
our transcriptome analysis identiﬁed several classes of candidate genes for PD mutations and may also provide insight
into the molecular pathways active in nigral dopaminergic neurons.
Key words: dopaminergic neurons; substantia nigra; neurodegenerative disease; candidate genes
1. Introduction
The neuropathological hallmark of Parkinson’s disease
(PD) is the progressive degeneration of dopaminergic
(DA) neurons in the substantia nigra pars compacta
(SNpc), affecting about 1–2% of the human population
older than 65 years.
1 It is characterized by the clinical
symptoms of resting tremor, muscular rigidity, postural
instability, a positive response to the administration
of L-DOPA, and the presence of cytoplasmic inclusions
in postmortem brains, Lewy Bodies.
2 Despite its mostly
sporadic onset and a high discordance rate in monozygo-
tic twins,
3 several human linkage studies had been
initiated to determine susceptibility genes for this
disease.
4 In the Online Mendelian Inheritance in Man
(OMIM) database, 13 PD loci have been recorded:
PARK1,
5 PARK2,
6–9 PARK3,
10 PARK4,
11,12
PARK5,
13 PARK6,
14,15 PARK7,
16,17 PARK8,
18
PARK9,
19,20 PARK10,
21 PARK11,
22,23 PaRK12,
23,24
and PARK13.
25 Furthermore, genome-wide analyses
of multiplex PD families provided evidence for linkage
to regions on different chromosomes.
21,22,24,26–29 The
PARK loci are sometimes larger than 10 Mb and can
contain hundreds of genes. In case of the genome-wide
linkage studies for a complex, multifactorial disease
such as PD, the regions with high LOD scores are
rarely smaller than 20 cM.
29 The differences among
independent studies and the size of the suggested
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DNA RESEARCH 14, 79–89, (2007) doi:10.1093/dnares/dsm007susceptibility regions make the searches for the under-
lying mutations irremediably a time-consuming process.
For several PARK loci, the searches have been success-
ful. Mutationsin a-synuclein(PARK1and PARK4), DJ-1
(PARK7), parkin (PARK2), PINK1 (PTEN-induced
putative kinase) (PARK6), LRRK2 (leucine-rich
repeat kinase 2) (PARK8), UCHL1 (ubiquitin carboxy-
terminal-hydrolase-L1) (PARK5), and ATP13A2
(ATPase type 13A2) (PARK9) have been identiﬁed.
5,30–37
Other studies have revealed the cytoskeletal protein
tau (MAPT)
36,38 and the ligand-independent nuclear
receptor NR4A2
30,39,40 (Nurr1) as susceptibility genes.
Although the deﬁnite role in PD of many of these genes
is still discussed and controversial (especially for NR4A2
and UCHL1) and the known mutations account for less
than 10% of all PD cases, the investigation into the
functions of the underlying genes has generated an
insight into the fundamental disease pathogenesis. For
example, a-synuclein and parkin turned out to be major
protein components of Lewy bodies in sporadic PD.
41
Mutations in parkin, UCHL1, and DJ-1 suggest that
abnormal protein folding and protein degradation
through the ubiquitin-proteasome system is an important
factor in the etiology of the disease.
42,43 PINK1 may
be involved in the phosphorylation of mitochondrial pro-
teins in response to cellular stress, thus protecting against
mitochondrial dysfunction.
35 Interestingly, mitochondria
are also the site, where the known neurotoxins for DA
neurons operate, suggesting that their malfunctioning
could be a major contributor to PD pathogenesis.
44
Current or future searches for the underlying mutations
in the remaining orphan Parkinson loci could be acceler-
ated and widened to promoter regions and to haplotype
variations, if the number of candidate genes is narrowed
down by other criteria. At least seven out of the
nine PD-associated genes are expressed by nigral DA
neurons,
45–50 with different expression levels and speci-
ﬁcity. These are a-synuclein, NR4A2, parkin,
46 PINK1,
tau, UCHL1, and LRRK1 (http://www.brain-map.org).
For this reason, we propose expression (speciﬁc or non-
speciﬁc) by mesDA neurons as a selection criterion to
identify candidate genes in those PD loci where the
underlying gene is still unknown (orphan). Such an
approach does not make any presumption with respect
to disease mechanisms. Conceptually, the same method
was applied on ﬁve large PD loci using serial analysis
of gene expression for a comparative expression anal-
ysis of SNpc and adjacent mesencephalon in postmortem
brains.
51 As cell-speciﬁc expression in mouse and human
is very similar, we took three murine expression studies
which employed ﬂuorescent-activated cell sorting (FACS)
and two unrelated subtractive methods for the identiﬁ-
cation of genes expressed by mesDA neurons.
52–54 We
collected the cDNA sequences of these expression anal-
yses from public databases, determined the underlying
genes and the corresponding gene ontology annotations
[Gene Ontology (GO)] to obtain insight into their function.
Then, we established their genetic locations and their syn-
tenic positions on the human genome. Finally, we
combined these data with existing human PD linkage
studies.
5–11,13–24,26–29,55,56
2. Material and methods
2.1. Transcriptome analysis
All nucleotide sequences used in this study are publicly
available at http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=Nucleotide and derived from three expression
analysesinmouse:(i)Barrettetal.
52published779sequences
(Accession Nos.: BE824469–BE824504, BE824506–
BE824519, BE824521–BE824561, BE824563–BE824823,
BE824825–BE825045, BE825047–BE825132, CK338036–
CK338155). (ii) Stewart et al.
53,57,58 published 496 cDNA
sequences (Accession Nos.: AA008736, W33210–W33212,
W33214–W33289, W35421–W35480, W36130–W36269,
W39787–W40005, W40007–W40008, W40010–W40023,
W45732). (iii) We published 160 sequences (Accession
Nos.: CO436137–CO436293).
54
Each nucleotide sequence was employed for a
nucleotide-nucleotide BLAST (blastn) (basic local align-
ment search tool) on the nr database (non-redundant)
(http://www.ncbi.nlm.nih.gov/BLAST/) and on the
mouse genome (http://www.ncbi.nlm.nih.gov/genome/
seq/MmBlast.html). We then recorded those alignments
with the highest scores, the lowest e-values, and highest
number of hits in a single locus. BLAST results were cate-
gorized into four groups: (1) no signiﬁcant alignments on
mouse genome (None), (2) signiﬁcant alignments with
mitochondrial DNA (Mitochondrial Genes), (3) multiple
high-scoring alignments on mouse genome (Multiple
Hits) for ambiguous results, and (4) signiﬁcant align-
ments on mouse genome for single hits or otherwise
unambiguous results (Table 1). The latter group was
further subdivided into: ‘Genes’, ‘ESTs’, and ‘genomic
Sequences’. The group ‘Genes’ comprises the results
with high-scoring alignments in exons of single genes.
In some cases, where the alignment lay in the region
after the last exon or, according to the chromosome
map view, in an intron of a given gene, we termed it
also ‘Gene’, if the hit was in a UniGene cluster which
was linked to the gene in the locus. With those
alignments that we were unable to associate to a gene,
we performed a blastn on the MmEST database. If we
could associate the sequence to a previously described
EST, we termed it ‘EST’; otherwise, it was termed
‘Genomic Sequence’.
For all the ‘Annotated Genes’, ‘Hypothetical Genes’,
and mitochondrial genes, the following data were col-
lected from the locus link feature (http://www.ncbi.nlm.
nih.gov/LocusLink this was replaced by http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene during the
80 Transcriptome Analysis and Parkinson’s Disease [Vol. 14,course of this study): the gene name, gene symbol, acces-
sion number, Gene ID, and the MGI link number, if avail-
able. The latter provides a relational link to the GO
library and the information related to ‘biological pro-
cesses’, ‘cellular components’, and ‘molecular functions’.
For all cDNA sequences categorized by ‘Signiﬁcant
Alignments on Mouse Genome’, we also registered the
exact chromosomal position in kilobases (starting from
the top of the short arm).
2.2. Mapping the murine cDNA sequences
to the human genome
For most of the murine genes, a human homolog has
already been determined, normally carrying the same
name and symbol. This information is registered on the
Entrez Gene page together with the cytogenetic locations.
When this information did not exist, we used the mouse
protein sequence of the identiﬁed gene for a translated
BLAST (tblastn), or the nucleotide sequence of the
cDNA fragment or the GenBank accession number of
the corresponding gene for a blastn on the human
genome. We registered the position in kilobases on the
chromosome and veriﬁed each position on the human
genome by comparing the neighboring genes to those in
the mouse genome and recorded the human position
only if the neighboring genes also matched.
When the cytogenetic position on the human genome
was determined, we compared this information with the
positions of the recorded PARK loci. We aligned the
human chromosome map view with the map for ‘morbid/
disease’, described in OMIM (http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db=OMIM). When the genes, or
the estimated human locations, and the cytogenetic
disease locations co-localized, we called the gene a PD
candidate gene. For the loci suggested by genome-wide
studies, we selected those genes, which were situated
+3 Mb from the chromosome marker (single nucleotide
polymorphism (SNP)) with the highest LOD score
(Table. 5). We are aware that this approach reduces the
numbers of genes in an arbitrary manner. However, if pre-
ferred, the range can be widened with the provided data
(see Supplementary Data) in order to more accurately con-
sider asymmetry or size of each speciﬁc linkage peak.
The entire data set was collected and processed using
the database program, Filemaker Pro 7.0. The latest
update was in February 2007. This database is available
upon request.
3. Results
We obtained 1435 sequences from three independent
studies, which had the original aim to identify genes
expressed by mesDA neurons. Barrett et al.
52 had isolated
DA neurons from E13 ventral midbrain by FACS. This
library contains genes expressed by mesDA neurons with
a preference for abundant genes. The other two studies
used subtractive methods to enrich for rare RNA tran-
scripts expressed by mesDA neurons. Stewart et al.
53,57,58
had created a single-stranded directional cDNA library
from substantia nigra of 8-week-old mice subtracted with
a cDNA library from cerebellum. We had used a PCR-
based differential display method
54 employing cDNA
from engrailed-1/2 double-mutant and wild-type ventral
midbrain during the embryonic stages when mesDA
neurons disappear in the mutants.
59,60 The ampliﬁed
sequences were compared to the expression proﬁle of
adult olfactory bulb, a source of DA neurons unrelated
to those in the ventral midbrain. Only differentially
expressed cDNA fragments were isolated and sequenced.
As the original sequence analyses of the former two
studies had been performed when a smaller nucleotide
data set was available and in order to update our own
expression analysis, we subjected the sequence data from
all three screens to new BLAST searches and determined
their association to genes and published ESTs, and their
location on the mouse genome. The 1435 cDNA frag-
ments generated 1050 unambiguous murine genomic
hits, 19 ambiguous multiple hits, and 104 alignments
with mitochondrial DNA. Two hundred and sixty-two
cDNA sequences produced no signiﬁcant alignments
(see Table 1 for deﬁnitions and the entire analysis, and
Table 2 for the individual libraries).
Out of 1050 cDNA fragments, which generated unam-
biguous alignments on the mouse genome, 1020 were in
gene loci. Most of them aligned to exons of those genes
(72.6%; 741 of 1020). Out these 1020 cDNA fragments,
181 (17.8%) lay 30 to the last annotated exon, suggesting
that substantial amounts of mRNAs isolated from brain
tissue are longer at their 30 end than mRNAs from other
Table 1. BLAST results on mouse genome
No signiﬁcant alignments on
mouse genome
262 None
Signiﬁcant alignments with
mitochondrial genes
104 Mitochondrial genes
Multiple high-scoring alignments
on mouse genome
19 Multiple hits
Signiﬁcant alignments on mouse
genome
1050 Genes (940)
Annotated genes (793)
Hypothetical genes (147)
ESTs (47)
Genomic sequences (63)
cDNA sequences are separated into four different categories
based on the types of alignments generated. Alignments on
the mouse genome were subdivided into Genes, ESTs, and
genomic sequences. For the category ‘Genes’, we differentiated
further between ‘annotated’ and ‘hypothetical’ depending on
the gene RefSeq status recorded at NCBI.
72
No. 2] D. Gherbassi et al. 81tissues (Table 3). Finally, 9.6% (98 of 1020) of the align-
ments lay in regions designated as introns, suggesting that
they are parts of unrecorded splice variants, possibly
speciﬁc for mesDA neurons.
The 1050 cDNA fragments represented 503 genes (423
annotated and 80 hypothetical genes), 32 ESTs, and 44
unique genomic hits with no otherwise described ESTs.
Additionally, the 104 sequences that aligned to the mito-
chondrial DNA represented 11 mitochondrial genes
(Table 2). To these cDNA sequences, we associated the
corresponding MGI numbers, if available. This provided
us with insight into their molecular function, the cellular
locations of the proteins, and the associated biological
process (see Supplementary Data for the entire trans-
criptome analysis). Several protein classes were over-
represented, like, for example, those, which take part in
mitochondria-related processes, in fatty acid chain metab-
olism, in ubiquitination, in the MAPK signaling pathways,
or which are chaperones. Some of these molecular pathways
were previously linked to the death of mesDA neurons, to
PD, and other human neurodegenerative disorders.
The majority of the mutations, which are associated to
PD, is in genes that are expressed in mesDA neurons. We,
therefore, joined these expression analyses with human
PD linkage and association studies,
5–11,13–24,26–29,55,56
where no mutation has been associated thus far. For
each unique mouse cDNA sequencing tag, we determined
its human homolog and the corresponding cytogenetic
and physical positions on the human chromosomes. We
veriﬁed each locus on the human genome by identifying
the neighboring genes on the mouse genome and recorded
the human position only if the adjacent genes were the
same. We then determined whether these positions were
within OMIM (Table 4) and other suggestive (non-
OMIM) PD loci (Table 5). In case of the OMIM orphan
PD loci, we projected on the human chromosome view
the map for ‘morbid diseases’. In case of non-OMIM
loci, we identiﬁed the genes +3 Mb to the SNP marker
with the highest LOD score. Totally, we linked the
mouse transcriptome analyses to 569 unique locations
on the human genome. Nineteen of these are within
orphan PARK loci (Table 6) and 51 in non-OMIM PD
loci (Table 7).
The experimental design of the three different tran-
scriptome analyses, we used for our study, were such
that they included both highly and rarely expressed tran-
scripts. Our analysis conﬁrmed the complementary nature
of the three screens. Only 7.2% (104 out of 1435) of the
cDNA sequences of these libraries represent genes,
hypothetical genes, or EST clusters, which are found in
Table 2. Classiﬁcation of BLAST results from each library
Total analysis Barrett
52 Stewart
53 Thuret
54
A. Number of unique alignments per individual library
Genes
a 423 150 218 77
Hyp. genes
b 80 23 39 19
ESTs
c 32 16 12 3
Genomic 44 15 8 21
Mitochondria 11 8 2 2
Multiple hits
d 14 6 4 4
None
e 185 67 111 8
Total
f 789 285 394 134
B. Total number of fragments
g
Genes
a 793 403 293 97
Hyp. genes
b 147 71 55 21
ESTs
c 46 28 15 5
Genomic 62 30 11 21
Mitochondria 104 100 2 2
Multiple hits
d 19 9 4 6
None
e 262 138 116 8
Total 1435 779 496 160
aAnnotated mouse genes.
bHypothetical genes determined by EST clustering or predicted
by automated computational genome analysis with a large open
reading frame.
cExpressed sequencing tags.
dUnderlying gene not identiﬁable, due to multiple alignments
with low e-values.
eNo hit in mouse and human genome.
fNumber of unique alignments. Five hundred and seventy-nine
unique tags were on the mouse genome (excluding mitochondria).
gNumber of fragments that represent genes, hypothetical genes,
ESTs, genomic sequences, multiple alignments, and mitochon-
drial genes, listed per individual library.
Table 3. Alignments in relation to gene loci
Total Genomic
sequences
ESTs Genes
In gene loci Only in last
exon
471 471
In last and
other exon(s)
132 132
a
Not in last
exon
138 138
After 30 end 181 6 16 159
Intron 98 40 10 48
Subtotal 1020 46 26 948
Outside
gene loci
30 17 13
Total 1050 63 39 948
Genomic alignments were divided into three groups: ‘ESTs’
(3.7%), ‘genomic sequences’ (6.0%), and ‘genes’ (90.3%).
Majority of the cDNA fragments that aligned with genes are
aligned with the last exon. A signiﬁcant number of the cDNAs
aligned with the region 30 to the last exon. See Material and
Methods for details.
aForty-four hits are in genes with only one exon.
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Locus OMIM identiﬁer Gene Cytogenetic location From (kb) To (kb) Mb Number of genes
PARK1 163890 SNCA 4q21.1-4q21.3
PARK2 602544 Parkin 6q25.3-6q26
PARK3 602404 2p13.3-2p13.1 68.075 75.307 7.2 106
PARK4 605543 4p15.33-4p15.1 13.424 37.324 23.9 60
PARK5 191342 UCHL1 4p14
PARK6 605909 PINK1 1p36.33-1p35.1
PARK7 602533 DJ1 1p36.23-1p36.22
PARK8 607060 12q11.2-12q13.13 27.908 55.637 27.7 351
PARK9 606693 ATP13A2 1p36.33-1p36.11
PARK10 606852 1p33-1p32.2 47.651 55.380 7.7 76
PARK11 607688 2q36.1-2q37.3 219.844 243.416 23.6 216
PARK12 300557 Xq21-q25 75.950 129.900 40.0 356
PARK13 610297 2p13.1-2p11.2 75.450 84.130 8.7 39
601828 NR4A2 2q22.1-2q23.3
603779 SNCAIP 5q23.1-q23.3
260540 MAPT 17q21.1
Genomic location of PARK loci as recorded in the OMIM databank. For seven of the PARK loci, the mutated genes were identiﬁed.
The number of genes is the current GenBank estimation of all annotated and predicted genes in the corresponding PARK locus. For
the PARK10 locus, we used the narrow deﬁnition 1p33-1p32.2 as determined by the two genetic markers D1S2134 and D1S200, and
not the entire shorter arm of chromosome 1 (1p) which contains 1232 genes.
21
Table 5. Association studies not recorded at OMIM
Cytogenetic location Genetic marker Mb CM Marshﬁeld LOD score
Bertoli-Avella (03)
27 19p13.13 D19S221 12.6 36 2.26
19p13.13 D19S840 13.7 38
DeStefano (01)
28 9q34.11 D9S1825 123.3 136 1.3
10q22.1 GATA121A08 70.2 88 1.07
DeStefano (02)
56 9q32 D9S930 110.6 120 1.86
20q11.2 D20S478 37.9 54 1.82
21q21 D21S2052 27.7 24 2.21
Hicks (02)
55 5q23.3 D5S666 120–137 135 1.6
Li (02)
21 10q25.3 D10S1237 116.1 134 2.62
6p21.1 D6S1017 41.7 63 1.88
5q15 D5S1462 96.4 105
5q21.1 Peak 100 108 1.65
5q21.3 D5S1453 105–109 115
17p13.1 D17S1303 10.8 24 1.93
Martinez (04)
29 2p12–q22 D2S2216 88 111 1.24
2p11–q12 Peak 102 117 2.04
2q12 D2S160 107 123 1.77
5q23 D5S471 117.5 130 1.05
6p12 D6S257 56 80 1.37
6q11–q13 Peak 69–73 85 1.41
6q14 D6S460  82 90 1.14
7p22 D7S531 3 5 1.51
Continued
No. 2] D. Gherbassi et al. 83Table 5. continued
Cytogenetic location Genetic marker Mb CM Marshﬁeld LOD score
11q14 D11S4175 89.9 91 1.6
19q13.3 D19S902 53.6 73 1.05
Pankratz (03)
24 Xq22.3 DXS8055 113.4 71 3.1
10q11.2 D10S196 51.5 70.0 2.3
Scott (01)
26 5q31.1 D5S816 135.4 139 2.39
17p11.2 D17S921 14.5 36 1.92
Two-point and multipoint LOD 17q11.2 D17S1293 32.7 56 2.28
17p11.2 D17S921 14.5 36 2.02
17q11.2 D17S1293 32.7 56 2.62
9q33.1 210 cM 117.8 130
Multipoint LOD 9q33.3 D9S301 66 cM 126.3 140 2.59
9q34.2 þ10 cM 132.3 150
3q13.32 D3S2460 118.7 135 1.62
For each individual study, the highest LOD scores with the associated genetic markers are listed. In these studies, the peak positions
and the ﬂanking genetic markers were given in centiMorgan on the Marshﬁeld genetic map. We determined, when possible, the exact
position in Mb on the corresponding chromosome. The average distance between the two adjacent genetic markers in each study
varied between 5 and 11 cM.
Table 6. Candidate genes in Orphan PARK loci
No. of cDNA
fragments aligning
with the gene
Mouse ID Human ID Symbol Human gene name Position Locus
1 NM_146169 XM_376062 KIAA1155 KIAA1155 protein 2p13.3 Park3
1 NM_008717 NM_014497 ZFML Zinc ﬁnger, matrin-like 2p13.2–p13.1 Park3
1 NM_183138 XM_371501 MGC22014 cDNA sequence BC037432 2p13.1 Park3
3 NM_080555 NM_003713 PPAP2B Phosphatidic acid phosphatase type 2B 1p32 Park10
1 AA819910 Estimated FAF1 In locus of Fas-associated factor 1 1p33 Park10
6 NM_009129 NM_003469 SCG2 Secretogranin II 2q35–q36 PARK11
3 AK052241 NM_005544 IRS1 Insulin receptor substrate 1 2q36 PARK11
1 NM_152915 NM_139072 DNER Delta/notch-like EGF-related receptor 2q37.1 PARK11
1 NM_008440 NM_004321 KIF1A Kinesin family member 1A 2q37.3 PARK11
2 NM_024197 NM_004544 NDUFA10 NADH dehydrogenase (ubiquinone) 1
alpha subcomplex 10
2q37.3 PARK11
1 NM_025437 NM_001412 EIF1AX Eukaryotic translation initiation factor
1A, X-linked
Xp22.13 PARK12
2 NM_019768 NM_012286 MORF4L2 Mortality factor 4 like 2 Xq22 PARK12
3 NM_011123 NM_000533 PLP1 Proteolipid protein 1 Xq22 PARK12
3 NM_013898 NM_004085 TIMM8A Translocase of inner mitochondrial
membrane 8 homolog a
Xq22.1 PARK12
3 NM_016783 NM_006667 PGRMC1 Progesterone receptor membrane
component 1
Xq22–q24 PARK12
7 NM_030688 estimated IL1RAPL2 After 30 of interleukin 1 receptor
accessory protein-like 2
Xq22.2–q22.3 PARK12
1 NM_133196 NM_001325 CSTF2 Cleavage stimulation factor, 30 pre-RNA,
subunit 2
Xq22.1 PARK12
1 NM_025893 NM_173798 ZCCHC12 Zinc ﬁnger, CCHC domain containing 12 Xq24 PARK12
2 NM_172782 NM_018698 NXT2 Nuclear transport factor 2-like export
factor 2
Xq23 PARK12
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GenBank ID Human ID Symbol Human
location
In kb
b Gene name
Scott (01) D3S2460
26
5 NM_008083 NM_002045 GAP43 3q13.1–13.2 116700 Growth-associated protein 43
3 BB626331 EST Lsamp 3q13.2–q21 117200 Limbic system-associated membrane protein
2 NM_177093 XM_057296 LRRC58 3q13.33 121300 Leucine-rich repeat containing 58
2 NM_008047 NM_007085 FSTl 3q13.32–q13.3 121460 follistatin-like 1
Martinez (04) D5S471
29
1 XM_283496 NM_005509 DMXL1 5q22 118600 Dmx-like 1
1 Genomic Estimated FEM1C 5q22 114939 fem-1 homolog c
3 NM_152809 NM_004384 CSNK1G3 5q23 123000 Casein kinase 1, gamma 3
Li (02) D5S1462 D5S1453
21
1 NM_172827 EST LNPEP 5q15 96440 Leucyl/cystinyl aminopeptidase
Hicks (02). Scott (01) D5S666. D5S816
26,55
1 NM_173753 NM_001008738 FNIP1 5q31.1 131060 Folliculin interacting protein 1
1 NM_144823 NM_015256 ACSL6 5q31 131400 Acyl-CoA synthetase long-chain family member
1 NM_033144 XM_034872 SEPT8 5q31 132180 Septin 8
1 AK011363 NM_003337 UBE2B 5q23–q31 133800 Ubiquitin-conjugating enzyme E2B, RAD6 homology
Scott (01) D5S816
26
1 NM_029518 NM_016604 JMJD1B 5q31 137810 Jumonji domain containing 1B
3 NM_010771 NM_018834 MATR3 5q31.3 138730 Matrin 3
Li (02) D6S1017
21
1 NM_025365 NM_013397 C6ORF49 6p21.31 41800 Chromosome 6 open reading frame 49
1 NM_020493 NM_003131 SRF 6p21.1 43200 Serum response factor (c-fos serum response element-binding
transcription factor)
5 NM_008302 NM_007355 HSP90AB1 6p12 44300 Heat shock protein 90 kDa alpha (cytosolic), class B member 1
Martinez (04) D6S257 D6S460
29
1 Genomic Estimated 6q12–q13 72500
8 NM_010106 NM_001402 EEF1A1 6q14.1 74224 Eukaryotic translation elongation factor 1 alpha 1
Martinez (04) D7S531
29
1 NM_028469 NM_032350 MGC11257 7p22.3 850 Hypothetical protein MGC11257
1 NM_010302 NM_007353 GNA12 7p22–p21 2510 Guanine nucleotide binding protein (G protein) alpha 12
6 NM_007393 NM_001101 ACTB 7p15–p12 5300 Actin beta
1 NM_026050 NM_032706 MGC12966 7p22.2 6110 Hypothetical protein MGC12966
1 NM_009007 NM_006908 RAC1 7p22 6170 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP
binding protein Rac)
DeStefano (01) D9S1825,
56 Scott (01) D9S301
26
7 NM_026434 NM_033117 RBM18 9q34.11 120400 RNA binding motif protein 18
2 NM_022310 NM_005347 HSPA5 9q33–q34.1 123370 Heat shock 70 kD protein 5
1 NM_025709 NM_015635 GAPVD1 9q34.11 123450 GTPase-activating protein and VPS9 domains 1
1 NM_172661 XM_497080 KIAA0515 9q34.1 129650 KIAA0515 gene
DeStefano (01) GATA121A08
56
1 NM_183295 NM_015634 KIAA1279 10q22.1 70100 KIAA1279 gene
Martinez (04) D11S4175
29
1 NM_025844 NM_012124 CHORDC1 11q14.3 89650 Cysteine and histidine-rich domain (CHORD)-containing. zinc-
binding protein 1
Continued
No. 2] D. Gherbassi et al. 85more than one of them (Table 8). Moreover, the libraries
also contained two cDNA fragments for a-synuclein, three
for NR4A2, and one for the tau genes. Mutations in all
three genes have been previously associated to PD.
5,30,36
Assuming that all 30 000 genes in the human genome
61
were equally likely detected, the probability to identify
three of nine PD susceptibility genes by chance out of a
pool of 569 was less than 3.4   10
23. If we exclude the
controversial NR4A2 and UCHL1, the probability was
less than 1.5   10
22.
4. Discussion
The entire human and mouse genome sequences have
been available for more than 3 years.
61,62 Therefore, the
chromosomal locations of most genes have been deter-
mined and as a consequence also those genes within a
given disease locus. In order to identify potential PD sus-
ceptibility genes, we projected the sequence data of three
murine transcriptome studies for mesDA neurons onto
the human genome and compared them with previously
Table 7. continued
GenBank ID Human ID Symbol Human
location
In kb
b Gene name
Li (02) D10S1239
21
1 NM_172523 NM_003054 VMAT2 10q25 118680 Solute carrier family 18
Li (02) D17S1303
21
1 NM_018768 NM_004853 STX8 17p12 9350 Syntaxin 8
Scott (01) D17S921, D17S1293
26
1 NM_011664 NM_018955 UBB 17p12–p11.2 16470 Ubiquitin B
1 NM_011480 NM_004176 SREBF1 17p11.2 17950 Sterol regulatory element binding factor 1
1 XM_110937 NM_145809 USP32 17p11.2 18621 Ubiquitin-speciﬁc protease 32
1 NM_026389 NM_015584 POLDIP2 17q11.2 26800 Polymerase delta interacting protein 2
1 NM_174852 NM_020889 PHF12 17q11.1 27400 PHD ﬁnger protein 12
1 NM_010897 NM_000267 NF1 17q11.2 29700 Neuroﬁbromatosis 1
1 NM_010161 NM_014210 EVI2A 17q11.2 29800 Ecotropic viral integration site 2A
1 NM_010716 NM_002311 LIG3 17q11.2–q12 33450 Ligase III, DNA, ATP-dependent
Bertoli-Avella (03) D19S221
27
2 NM_008319 NM_003259 ICAM5 19p13.2 10260 Intercellular adhesion molecule 5, telencephalin
16 NM_016742 NM_007065 CDC37 19p13.2 10370 Cell division cycle 37 homolog (S. cerevisiae)-like
1 NM_145624 NM_016264 ZNF44 19p13.2 12200 Zinc ﬁnger protein 44
1 NM_010906 NM_002501 NFIX 19p13.3 13030 Nuclear factor I/X
1 NM_183097 Estimated 19p13.13 14060 Progestin and adipoQ receptor family member
DeStefano (02) D20S478
56
1 BQ927659 Estimated 20q11.2–q12 35330
1 NM_013865 NM_022477 NDRG3 20q11.21–
q11.23
36000 n-myc downstream regulated 3
1 NM_010658 NM_005461 MAFB 20q11.2–q13.1 40000 v-maf musculoaponeurotic ﬁbrosarcoma oncogene family. protein
B
2 NM_021464 NM_007050 PTPRT 20q12–q13 40500 Protein tyrosine phosphatase. receptor type T
DeStefano (02) D21S2052
56
2 NM_11782 Estimated ADAMTS5 21q21.2 27170 A disintegrin-like and metalloprotease (reprolysin-type) with
thrombospondin type 1 motif 5 (aggrecanase-20)3 0
Pankratz (03) DXS8055
24
1 NM_016783 NM_006667 PGRMC1 Xq24 116713 Progesterone receptor membrane component 1
Listed genes are situated +3 Mb to peak with the highest LOD score, except for D10S196 where we used +8Mb.
aNumber of cDNA fragments aligning with the gene.
bkb from the top of the short arm of the chromosome.
cHuman chromosome location was estimated by comparing the ﬂanking regions of mouse and man.
86 Transcriptome Analysis and Parkinson’s Disease [Vol. 14,identiﬁed PD loci. We determine the human homologs of
1435 murine cDNA fragments which corresponded to 579
unique mouse chromosomal locations; 423 annotated
genes, 80 hypothetical genes, 32 ESTs, and 44 genomic
locations, which are not linked to any genes or otherwise
reported cDNA sequences. Of the 569 unique locations on
the human genome, 19 were positioned in OMIM PARK
loci and 51 within genomic regions that have a weaker
linkage to PD, which are not recorded in the OMIM data-
base and need further conﬁrmation.
Multiple studies are on the way to determine the under-
lying mutations of orphan PARK loci
63; however, the
length of putative regulatory regions of most gene, their
unpredictable position, and the common presence of
SNPs have thus far restricted such studies to nucleotide
variation in the coding region and in 50 and 30 UTR.
Disparities in the promoter–enhancer–silencer regions
were only the aim if the targeted gene had been previously
linked to PD.
64,65 A nucleotide variation in the a-synu-
clein promoter, for example, was associated to the
disease.
12,66 Variability on the level of gene expression is
far more common than nucleotide variations which alter
protein sequences
67 and it is believed that these haplotype
variations determine individual traits and predispositions
for common diseases such as PD. Narrowing down the
number of candidate genes in identiﬁed loci in a rational
manner may encourage the inclusion of the promoter
regions in future studies aiming to identify mutations
associated to PD.
Among the candidate genes that we found, the most
interesting is VMAT2 (vesicular monoamine transporter 2)
(10q25). Reduced expression of VMAT2 could be
correlated with a higher sensitivity to environmental
factors. For example, VMAT2 heterozygote mice (þ/ 2 )
are remarkably more sensitive than wild-type to the neuro-
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
68,69
Furthermore, we identiﬁed two genes in the ubiquitination
pathway, Ube2b [ubiquitin-conjugating enzyme E2B,
RAD6 homology (S. cerevisiae)] and Ubb (Ubiquitin B,
member of the HSP90 family) and Hspa5 (heat shock
70 kDa protein 5, member of the HSP70 family).
Finally, 26 mitochondrial genes encoded by nuclear DNA
arepresentinourtranscriptomeanalysis.Ofthese,anunex-
pected high proportion of genes, namely four, are located
within orphan OMIM PARK loci. There is increasing evi-
dence that impairment of mitochondrial functions and oxi-
dative stress are contributing factors to PD
70 supported by
the recent ﬁnding of a mutation in PINK1.
35 Furthermore,
the functional deﬁciencies induced by several of the other
PD mutations seem to converge onto the mitochondria.
71
Our ﬁnding conﬁrms a central role of the mitochondria in
PD and suggests the possibility that a misregulation of
some of these four mitochondrial genes may be a contribut-
ing factor for the disease.
We conclude that our transcriptome analysis, along
with being applicable for the identiﬁcation of PD candi-
date genes, may also be a useful tool for future genome-
wide association studies with newer resources, such as
HapMap (http://www.hapmap.org/), where tagSNPs
can be chosen close to loci of genes expressed by mesDA
neurons. Furthermore, new GO annotations are con-
stantly added and with time it may turn out that many
of the identiﬁed genes are part of shared metabolic path-
ways. Our data set may give new insight into ligand/
receptor interactions and/or intracellular signaling path-
ways acting in mesDA neurons, allowing novel studies
into the molecular etiology of PD.
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